1. Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect of losartan plus trandolapril compared with the effect of either agent alone on end point (time to d...
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect of losartan plus trandolapril compared with the effect of either agent alone on end point (time to doubling of serum creatinine or ESRD). Patients did not have diabetes and had hypertension and chronic nephropathy. Reprinted from reference (17), with permission.
George L. Bakris CJASN 2008;3:S3-S10
©2008 by American Society of Nephrology